A randomised open label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of 8 weekly dual long-acting injectable antiretroviral therapy (ART) compared to daily oral dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years in sub-Saharan Africa